The Global Meniere’s Disease Market is growing moderately and is expected to continue
its growth during the forecast period. Global Meniere’s disease market is expected to grow
at the CAGR of ~5.4% during the forecast period and is estimated to reach USD 6380.3
million by 2023.
The prevalence and incidence of Meniere’s disease is increasing. According to the National
Institute on Deafness and Other Communication Disorders, there are around 615,000
Americas who are suffering from Meniere’s disease. This number is continuously growing
every year. According to Massachusetts Eye and Ear (An international center for treatment
and research and a teaching hospital of Harvard Medical School), approximately 60,000 new
cases of this disease are diagnosed annually.
Companies are working on this disease by investing in research and new product
development that can cure this disease. Top pharmaceutical companies like F. Hoffmann-La
Roche Ltd, Novartis AG and Pfizer Inc. are exploring new options for the treatment of
Meniere’s disease. These companies have already started clinical trials for this disease. US
based company Otonomy Inc. raised USD 115 million in 2014 for clinical trials for drug that
can quiet the overexcitement of the signalingbetween nerve cells in the cochlea that is
linked to tinnitus. Otonomy Inc. is also testing a steroid gel to treat Meniere’s disease.
Increasing awareness of this disorder is another important factor for the market growth.
Some other factors such as technological advancement, introduction and rapid adoption of
therapies are also leading the market growth. Increasing demand from emerging markets of
Asia and Latin America are creating smooth path for the market growth.
Key players for global Meniere’s disease market:
Auris Medical (Switzerland), Jubilant Cadista (US), Otonomy Inc.(US), Prestige Brands
Holdings, Inc. (US), Sound Pharmaceuticals (US), The Ear Company (Canada), WellSpring
Pharmaceutical Corporation (US) and others.
Get Sample copy at https://www.marketresearchfuture.com/sample_request/3991 .
Segments:
Global Meniere’s Disease Market has been segmented on the basis of diagnosis which
comprise of hearing assessment, balance assessment, blood tests, imaging test, and others.
Balance assessment is sub-segmented into Videonystagmography (VNG), Rotary-chair
testing, Vestibular evoked myogenic potentials (VEMP) testing, posturography, video Head
Impulse Test (vHIT), Electrocochleography (ECoG), and others. Imaging test includes
Magnetic Resonance Imaging (MRI) and others.
On the basis of treatments, the market has been segmented into medication, noninvasive
therapies & procedures, middle ear injections, surgery, and others. Medication is sub-
segmented into motion sickness medications, anti-nausea medications, and others.